Weight gain on HIV treatment greater in people who start treatment with advanced HIV
Weight loss after treatment switch more likely for those with higher body mass
Switching to injectable cabotegravir and rilpivirine rarely affects body weight
Switching from TAF to older tenofovir may halt or reverse weight gain and lipid increases
Dolutegravir has direct effects on fat cells
Weight gain on treatment: more evidence that TAF plus dolutegravir leads to greater gains
Substantial weight gain as dolutegravir is rolled out in Africa
Women with HIV at greater risk of diabetes than men
Obesity more important than integrase inhibitors in risk for developing diabetes in people with HIV
